November 16 - 18, 2020
2020 Healthcare Enforcement Compliance Conference
Virtual , Central Standard Time (CST)Handouts
Monday, November 16
General Session: Government Enforcement Panel |
101 Anti-Kickback Statute Case Studies and OIG’s Regulatory Flexibilities During the COVID-19 Pandemic |
102 False Claims Act Liability in Post-Acute Care |
103 Preventing Enforcement Actions in Clinical Research: Operational Strategies for Avoiding Financial Frauds |
201 Managed Care Enforcement and Compliance |
202 How OIG Uses Data in its Affirmative Cases & How Data Can be Incorporated into Compliance |
203 The Myth(s) of Median to 75th: New Perspectives on Assessing, Managing and Monitoring Physician Compensation Arrangement Risk |
General Session: Whistleblowers: Who Are They, Why Do They Bring Cases, and What Makes a Good Whistleblower Case |
301 Federal Administrative Sanctions |
302 DOJ Updated Guidance: June 2020 |
303 Lessons Learned from Stark Investigations |
401 Enforcement and Compliance for Pharmacies |
402 Why Whistleblowers Matter to Healthcare Compliance |
403 Trends and Best Practices in Healthcare Privacy and Security InvestigationsPresentation |
501 Self-Disclosure Protocol |
502 The Secret Sauce for Complying with Privacy Regulations |
503 Encryption: Policy to Practice, Lower Risk, Increase Compliance |
Tuesday, November 17
General Session: CMS Update |
601 Negotiating CIAs: What’s New, What’s Different, What Do You Need to Know? |
602 Civil and Criminal Telehealth Enforcement Matters; DME, Pharmaceutical and Other Covered Items and Services |
603 Understanding and Preserving Privilege During Compliance Investigations |
701 Laboratory Enforcement and Compliance |
702 340 B Compliance |
703 Three Competing Perspectives on Federal Healthcare Enforcement Trends: Federal Prosecutor, InHouse Counsel, Outside Counsel |
General Session: DOJ’s Consumer Protection Branch: Safeguarding Americans from Dangerous Drugs and Devices |
801 Get ‘Em Where it Hurts: Using Compensation to Influence Compliance |
802 Enforcement and Compliance Risks Associated with the Opioid Crisis: Who's to Blame Will Cast a Wide Net |
803 Ask the Stark Professionals |
901 CMS Oversight and Enforcement of Safety and Quality Standards |
902 Big Data: How Can It Be Shared and What Are the Considerations Regarding Enforcement? |
903 Hot OIG Target Area: Device Reporting & Related Outlier |
Wednesday, November 18
W1 Compliance, Internal Investigations and Self Disclosure: Building the Team, Process, and Resolution |
W2 Medical Necessity and Civil and Criminal Liability |
W3 Electronic Health Records Fraud Enforcement: What, Why, and Thoughts for Compliance Professionals |
W4 Negotiating and Mediating False Claims Act Cases |
W5 Compliance Officers, General Counsel and Enforcement |
W6 Data Analytics and AI to Detect and Defend Fraud |
W7 Anatomy of a False Claims Act Case |
W8 Medicaid Fraud Enforcement Update |
W9 Litigating a False Claims Act Case |
W10 CIAs and IROs: What Are They and Why Do They Matter? |
W11 Is your Conflicts of Interest Program Effective? |
W12 Understanding the Components of a Comprehensive Compliance Risk Assessment Process |
W13 Strategies and Best Practices for Responding to Enforcement Activities |
W14 Handling a Criminal Healthcare Fraud Case |
W15 Root Cause Analysis Workshop |